알자멘드 뉴로(ALZN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.89 (+2.72%), 시가총액 $0.00B, 52주 최저~최고 $0.54 ~ $5.44.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is
알자멘드 뉴로의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
알자멘드 뉴로의 현재 주가는 $1.89 (+2.72%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
알자멘드 뉴로의 시가총액은 약 $0.00B입니다.
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001,